UnknownNot Applicable

Plan for Testing Fingerstick Bloods on Magellan Systems

United States190 participantsStarted 2017-07-31

Plain-language summary

This study is to supplement our internal data that demonstrates the continued performance of capillary blood samples on Magellan's lead testing systems: LeadCare II, LeadCare Ultra (which have been cleared previously by FDA), and PediaStat, which is an upgraded LeadCare II instrument in development.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * healthy subjects who consent to a capillary blood collection Exclusion Criteria: * Patients are not currently taking chelating agents, e.g., penicillamine, succimer

What they're measuring

Lead poisoning

Timeframe: 1 day

Trial details

NCT IDNCT03256383

SponsorMagellan Diagnostics

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2017-08-31

Contact for this trial

Catherine Lufkin

978-248-4963 Catherine.Lufkin@magellandx.com

View on ClinicalTrials.gov More Lead Poisoning trials